Detalle Publicación

Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer
Autores: Gettinger, S. (Autor de correspondencia); Choi, J.; Hastings, K.; Truini, A.; Datar, I.; Sowell, R.; Wurtz, A.; Dong, W.; Cai, G.; Melnick, M. A.; Du, V. Y.; Schlessinger, J.; Goldberg, S. B.; Chiang, A.; Fernández de Sanmamed Gutiérrez, Miguel; Melero Bermejo, Ignacio; Agorreta Arrazubi, Jackeline; Montuenga Badía, Luis; Lifton, R.; Ferrone, S.; Kavathas, P.; Rimm, D. L.; Kaech, S. M.; Schalper, K.; Herbst, R.S.; Politi, K.
Título de la revista: CANCER DISCOVERY
ISSN: 2159-8274
Volumen: 7
Número: 12
Páginas: 1420 - 1435
Fecha de publicación: 2017
Mechanisms of acquired resistance to immune checkpoint inhibitors (ICI) are poorly understood. We leveraged a collection of 14 ICI-resistant lung cancer samples to investigate whether alterations in genes encoding HLA Class I antigen processing and presentation machinery (APM) components or interferon signaling play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies. Recurrent mutations or copy-number changes were not detected in our cohort. In one case, we found acquired homozygous loss of B2M that caused lack of cell-surface HLA Class I expression in the tumor and a matched patient-derived xenograft (PDX). Downregulation of B2M was also found in two additional PDXs established from ICI-resistant tumors. CRISPR-mediated knockout of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo, proving its role in resistance to ICIs. These results indicate that HLA Class I APM disruption can mediate escape from ICIs in lung cancer. SIGNIFICANCE: As programmed death 1 axis inhibitors are becoming more established in standard treatment algorithms for diverse malignancies, acquired resistance to these therapies is increasingly being encountered. Here, we found that defective antigen processing and presentation can serve as a mechanism of such resistance in lung cancer.